ArticlePloS one2024
Identifying potential drug targets for myocardial infarction through Mendelian randomization.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study explored the associations between plasma and cerebrospinal fluid (CSF) proteins and myocardial infarction (MI) risk. Identifying specific proteins as biomarkers for MI could enhance our understanding of disease mechanisms and inform clinical practice.
methodsWe combined protein quantitative trait loci (pQTL) data for plasma and CSF proteins with genome-wide association study (GWAS) summary statistics for MI. Mendelian Randomization (MR) analyses were conducted to establish causal relationships, supported by Bayesian colocalization and Spearman correlation analyses. For plasma proteins, we used pQTL data from Cheng et al. to select 738 cis-acting SNPs associated with 734 proteins. The "TwoSampleMR" method and inverse-variance weighted MR were applied for evaluations.
resultsIn plasma, CD8A and HDHD2 were identified as protective factors against MI, while DPEP1 was linked to increased risk. In CSF, CD30 Ligand was associated with MI risk. Bayesian colocalization supported the association for CD8A in plasma. No significant correlation was found between plasma and CSF results, suggesting distinct mechanisms for these biomarkers.
conclusionOur study identified several plasma and CSF proteins linked to MI risk, offering new insights into the disease's biological underpinnings. These findings could guide future research on MI biomarkers and contribute to improved prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.